Low-Dose Dexamethasone Does Not Abrogate the Immunomodulatory Effects of Lenalidomide and Both Reactivate the Impaired Immune System of High-Risk Smoldering Multiple Myeloma Patients

被引:0
|
作者
Paiva, Bruno [1 ]
Mateos, Maria-Victoria [2 ]
Ignacio Sanchez-Abarca, Luis [3 ]
Belen Vidriales, Maria [4 ]
Lopez-Corral, Lucia [5 ]
Corchete, Luis A. [5 ]
Hernandez, Miguel T. [6 ]
Bargay, Joan [7 ]
De Arriba, Felipe [8 ]
De la Rubia, Javier [9 ]
Isabel Teruel, Ana [10 ]
Giraldo, Pilar [11 ]
Rosinol, Laura [12 ]
Prosper, Felipe [13 ]
Oriol, Albert [14 ]
Mariano Hernandez, Jose [15 ]
Esteves, Graca [16 ]
da Costa, Fernando Leal [17 ]
Jose Lahuerta, Juan [18 ]
Blade, Joan [12 ]
Perez-Simon, Jose A. [19 ]
San Miguel, Jesus [20 ]
机构
[1] Univ Navarra Clin, Dept Hematol & Immunol, Pamplona, Spain
[2] Univ Hosp Salamanca IBSAL, Dept Hematol, Salamanca, Spain
[3] IBSAL Hosp Univ Salamanca, Serv Hematol, Salamanca, Spain
[4] Hosp Univ Salamanca, Dept Hematol, Salamanca, Spain
[5] Hosp Univ Salamanca, Salamanca, Spain
[6] Univ Hosp, Santa Cruz, CA USA
[7] Hosp Son Llatzer, Palma de Mallorca, Spain
[8] Hosp Univ Morales Meseguer, Ctr Reg Hemodonac, Hematol & Clin Oncol Unit, Murcia, Spain
[9] HUP La Fe, Valencia, Spain
[10] Hosp Clin Valencia, Valencia, Spain
[11] Minist Publ Hlth Russia, Hematol Res Ctr, Moscow, Russia
[12] Hosp Clin Barcelona, Barcelona, Spain
[13] Univ Navarra Clin, Pamplona, Spain
[14] Hosp Badalona Germans Trias & Pujol, lnst Catala Oncol, Barcelona, Spain
[15] Hosp Gen Segovia, Segovia, Spain
[16] Hosp Santa Maria, Lisbon, Portugal
[17] nst Portugues Oncol, Lisbon, Portugal
[18] Hosp 12 Octubre, E-28041 Madrid, Spain
[19] Hosp Univ Virgen Rocio, Dept Hematol, Seville, Spain
[20] Univ Navarra, Univ Navarra Clin, Ctr Invest Med Aplicada, E-31080 Pamplona, Spain
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页数:3
相关论文
共 50 条
  • [21] Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study
    Suzuki, Kenshi
    Shinagawa, Atsushi
    Uchida, Toshiki
    Taniwaki, Masafumi
    Hirata, Hirokazu
    Ishizawa, Kenichi
    Matsue, Kosei
    Ogawa, Yoshiaki
    Shimizu, Takayuki
    Otsuka, Maki
    Matsumoto, Morio
    Iida, Shinsuke
    Terui, Yasuhito
    Matsumura, Itaru
    Ikeda, Takashi
    Takezako, Naoki
    Ogaki, Yumi
    Midorikawa, Shuichi
    Houck, Vanessa
    Ervin-Haynes, Annette
    Chou, Takaaki
    CANCER SCIENCE, 2016, 107 (05) : 653 - 658
  • [22] Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment
    Zhou, Dao-bin
    Yu, Li
    Du, Xin
    Jin, Jie
    Cai, Zhen
    Chen, Fangping
    Ke, Xiaoyan
    Li, Xiao
    Wu, Depei
    Meng, Fanyi
    Ai, Huisheng
    Zhang, Jingshan
    DeMarco, Dena
    Chen, Nianhang
    Mei, Jay
    Wang, Jianmin
    Hou, Jian
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (06) : 569 - 577
  • [23] Interim Results of a Phase 2 Trial of Isatuximab-Lenalidomide for Patients with High-Risk Smoldering Multiple Myeloma
    Thomas, Sheeba
    Manasanch, Elisabet
    Korde, Neha
    Lee, Hans
    Jagannath, Sundar
    Becnel, Melody
    Kaufman, Gregory
    Patel, Krina
    Iyer, Swaminathan
    Mailankody, Sham
    Weber, Donna
    Lutter-Berka, Zuzana
    Carpenter, Shawnee
    Nolasco, David Berrios
    Hildebrandt, Michelle
    Feng, Lei
    Amini, Behrang
    Neelapu, Sattva
    Orlowski, Robert
    Landgren, Ola
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S27 - S27
  • [24] A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Lonial, Sagar
    Jakubowiak, Andrzej J.
    Jagannath, Sundar
    Raab, Marc S.
    Facon, Thierry
    Vij, Ravi
    Moreau, Philippe
    Reece, Donna E.
    White, Darrell J.
    Benboubker, Lotfi
    Zonder, Jeffrey A.
    Rossi, Jean-Francois
    Tsao, Claire
    Parli, Teresa
    Kroog, Glenn
    Singhal, Anil K.
    Richardson, Paul G.
    BLOOD, 2011, 118 (21) : 141 - 142
  • [25] Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma
    Kobayashi, Tsutomu
    Kuroda, Junya
    Fuchida, Shin-ichi
    Kaneko, Hitomi
    Yagi, Hideo
    Shibayama, Hirohiko
    Tanaka, Hirokazu
    Kosugi, Satoru
    Uoshima, Nobuhiko
    Kobayashi, Masayuki
    Adachi, Yoko
    Ohta, Kensuke
    Ishii, Kazuyoshi
    Uchiyama, Hitoji
    Matsuda, Mitsuhiro
    Nakatani, Eiji
    Tsudo, Mitsuru
    Shimazaki, Chihiro
    Takaori-Kondo, Akifumi
    Nomura, Shosaku
    Matsumura, Itaru
    Taniwaki, Masafumi
    Kanakura, Yuzuru
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (01) : 37 - 45
  • [26] Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma
    Tsutomu Kobayashi
    Junya Kuroda
    Shin-ichi Fuchida
    Hitomi Kaneko
    Hideo Yagi
    Hirohiko Shibayama
    Hirokazu Tanaka
    Satoru Kosugi
    Nobuhiko Uoshima
    Masayuki Kobayashi
    Yoko Adachi
    Kensuke Ohta
    Kazuyoshi Ishii
    Hitoji Uchiyama
    Mitsuhiro Matsuda
    Eiji Nakatani
    Mitsuru Tsudo
    Chihiro Shimazaki
    Akifumi Takaori-Kondo
    Shosaku Nomura
    Itaru Matsumura
    Masafumi Taniwaki
    Yuzuru Kanakura
    International Journal of Hematology, 2015, 101 : 37 - 45
  • [27] A RANDOMIZED PHASE 2 STUDY OF ELOTUZUMAB WITH LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Moreau, P.
    Richardson, P.
    Jakubowiak, A.
    Jagannath, S.
    Raab, M.
    Facon, T.
    Vij, R.
    Reece, D.
    White, D.
    Benboubker, L.
    Zonder, J.
    Rossi, J. F.
    Tsao, C.
    Parli, T.
    Kroog, G.
    Singhal, A.
    Lonial, S.
    HAEMATOLOGICA, 2012, 97 : 474 - 474
  • [28] LENALIDOMIDE PLUS HIGH-DOSE VERSUS LOW-DOSE DEXAMETHASONE FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC REVIEW
    Kupas, K.
    Kaspar, I.
    Baecke, V.
    Weisel, K.
    HAEMATOLOGICA, 2017, 102 : 514 - 515
  • [29] Early intervention for high-risk and low-risk of progression for patients with smoldering multiple myeloma.
    Sweeney, Nathan W.
    Cheung, Christian S.
    Molina, Thomas H.
    Ahlstrom, Jennifer M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] Dose-adjusted Lenalidomide Combined with Low-dose Dexamethasone Rescues Older Patients with Bortezomib-resistant Multiple Myeloma
    Yamasaki, Satoshi
    Kohno, Kentaro
    Kadowaki, Masanori
    Takase, Ken
    Okamura, Seiichi
    INTERNAL MEDICINE, 2015, 54 (14) : 1711 - 1715